Namely, this special purpose acquisition vehicle (SPAC) that sought to acquire companies in the clinical diagnostic sector in Europe and Asia will officially begin trading on the LSE as of today, July 8, under the ticker symbol SPMU. Further, the listing will consist of 49,300,000 ordinary shares admitted to the Standard Listing segment of the Official List of the Financial Conduct Authority. In short, the SPAC was established in 2021 by Zaccheus Peh, an experienced entrepreneur in the clinical diagnostics, laboratory services, and medical services businesses. Furthermore, with the company’s board, the SPAC has identified a couple of potential take-over targets; yet, at this moment, they do not have a specific initial acquisition under consideration.
Watershed moment
Possible acquisitions, under Chapter 5 of the Listing Rules, will be treated as a reverse takeover, along with any subsequent acquisition or investment by the company, depending on the size and nature of the takeover. Zaccheus Peh, Non-Executive Chairman of Spiritus Mundi, said in the announcement: He added: On the whole, the company managed to secure funding of over £1.2 million (~$1.44 million) in its pre-IPO stage and is run by two proposed directors that ran a laboratory business with revenue of over $2.7 billion. Market participants have an opportunity to get in on the ground floor or rather track the development of the SPAC and jump on board once a potential acquisition target has been made public. Buy stocks now with Interactive Broker – the most advanced investment platform Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
